VTR TIAlternative Names: VTR-TI
Latest Information Update: 06 Dec 2007
At a glance
- Originator CSL Behring
- Developer CSL Behring; Curacyte AG
- Mechanism of Action Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Deep vein thrombosis
Most Recent Events
- 16 Jun 2004 No development reported - Preclinical for Deep vein thrombosis in Germany (unspecified route)
- 01 Apr 2004 Aventis Behring LLC has merged with ZLB Bioplasma to form ZLB Behring
- 10 Jun 2002 VitaResc Biotech has been acquired by, and merged into, Curacyte AG